EPIGRAL vs ROSSARI: Stock Comparison
EPIGRAL is the larger company by market capitalisation. EPIGRAL shows a higher ROE, a higher dividend yield and lower leverage, while ROSSARI BIOTECH shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
EPIGRAL leads 7; ROSSARI leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | EPIGRAL | ROSSARI |
|---|---|---|
| Sector | Chemicals | Chemicals |
| Industry | Specialty Chemicals | Specialty Chemicals |
Price
| Metric | EPIGRAL | ROSSARI |
|---|---|---|
| Live Price | ₹1,131.1 | ₹446.15 |
| Day Change | -1.63% | -0.75% |
| Volume | 22,425 | 36,449 |
| 52-Week High | ₹1,808.8 | ₹690.3 |
| 52-Week Low | ₹807 | ₹375 |
| Distance from 52W High | -37.47% | -35.37% |
Valuation
| Metric | EPIGRAL | ROSSARI |
|---|---|---|
| Market Cap | ₹4,888 Cr | ₹2,491 Cr |
| P/E Ratio | 18.03x | 16.53x |
| P/B Ratio | 2.2x | 1.87x |
| EPS | ₹22.99 | ₹6.34 |
| Book Value | ₹514.92 | ₹240.71 |
| Dividend Yield | 0.44% | 0.11% |
Growth
| Metric | EPIGRAL | ROSSARI |
|---|---|---|
| Revenue Growth (TTM YoY) | 17.3% | 18.2% |
| EPS Growth (TTM YoY) | -6.8% | 33.5% |
| Qtr Sales Growth | 0% | 44.56% |
| Qtr Profit Growth | -0.56% | 2.42% |
Profitability & Leverage
| Metric | EPIGRAL | ROSSARI |
|---|---|---|
| ROE | 14.94% | 11.19% |
| ROCE | 11.04% | 10.1% |
| Net Margin | 13.14% | 6.14% |
| Operating Margin | 16.37% | 9.56% |
| Debt to Equity | 0.25x | 0.31x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | EPIGRAL | ROSSARI |
|---|---|---|
| Promoter Holding | 68.83% | 63.63%▼ 0.01 pp |
| FII Holding | 1.03%▼ 0.51 pp | 2.02%▼ 0.16 pp |
| DII Holding | 5.56%▲ 0.66 pp | 14.64%▼ 3.56 pp |
| Public Holding | 24.55%▼ 0.15 pp | 15.2%▲ 3.74 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: EPIGRAL and ROSSARI BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.